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Mitral valve prolapse (MVP) is a common cardiovascular abnormality in the United States, occurring in ∼2.4%
of the general population. Clinically, patients with MVP exhibit fibromyxomatous changes in one or both of the
mitral leaflets that result in superior displacement of the leaflets into the left atrium. Although often clinically
benign, MVP can be associated with important accompanying sequelae, including mitral regurgitation, bacterial
endocarditis, congestive heart failure, atrial fibrillation, and even sudden death. MVP is genetically heterogeneous
and is inherited as an autosomal dominant trait that exhibits both sex- and age-dependant penetrance. In this
report, we describe the results of a genome scan and show that a locus for MVP maps to chromosome 11p15.4.
Multipoint parametric analysis performed by use of GENEHUNTER gave a maximum LOD score of 3.12 for the
chromosomal region immediately surrounding the four-marker haplotype D11S4124-D11S2349-D11S1338-
D11S1323, and multipoint nonparametric analysis (NPL) confirms this finding ( ; ).NPLp 38.59 Pp .000397
Haplotype analysis across this region defines a 4.3-cM region between the markers D11S1923 and D11S1331 as
the location of a new MVP locus, MMVP2, and confirms the genetic heterogeneity of this disorder. The discovery
of genes involved in the pathogenesis of this common disease is crucial to understanding the marked variability in
disease expression and mortality seen in MVP.
Originally described in the 1960s, mitral valve prolapse
(MVP [MIM 157700]) is a very common Mendelian car-
diovascular disorder (Barlow and Bosman 1966; Dev-
ereux et al. 1982). It is characterized by systolic dis-
placement or billowing of the mitral leaflets into the left
atrium, often accompanied by mitral regurgitation (MR).
The leafletsmay be thickened, showmyxomatous changes
with altered collagen and elastin composition, show dis-
ruption of the fibrous backbone, and show proteoglycan
accumulation (Cole et al. 1984; Tamura et al. 1995).
Complications include bacterial endocarditis, progressive
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MR, arrhythmias, and even sudden death (Devereux et
al. 1987, 1989; Levy and Savage 1987; Perloff and Child
1987; Braunwald 1992; Avierinos et al. 2002), and it is
the leading cause of isolated MR requiring surgical re-
pair (Waller et al. 1982).
Familial studies of idiopathic or nonsyndromic MVP
suggest an autosomal dominant mode of inheritance with
incomplete penetrance (Weiss et al. 1975; Fortuin et al.
1977; Devereux et al. 1982). Additionally, sex- and age-
dependent penetrance has been noted, with MVP being
more prevalent in females and with increasing age (Weiss
et al. 1975; Devereux et al. 1982; Strahan et al. 1983).
The clinical heterogeneity observed within families is of-
ten striking, with severe valvular abnormalities seen in
several patients, whereas other affected family members
show only moderate or slight changes (Zuppiroli et al.
1998). MVP has been reported in association with many
genetic connective-tissue disorders, includingMarfan syn-
drome, Ehlers-Danlos syndrome, osteogenesis imper-
fecta, dominant cutis laxa, and pseudoxanthoma elas-
ticum (Malcom 1985; Glesby and Pyeritz 1989; Struk
et al. 1997; Milewicz 1998; Rubegni et al. 2000). A
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search of Online Mendelian Inheritance in Man reveals
a multitude of entries for whichMVP is a clinical feature,
including a recent clinical and genetic study in which
MVP has been proposed to be involved in panic disorder
syndrome (Weissman et al. 2000). Despite the associa-
tion of MVP with various connective-tissue disorders,
linkage to several fibrillin and collagen genes has been
excluded (Henney et al. 1989; Wordsworth et al. 1989).
Initial attempts to establish a genetic basis for MVP
were limited by nonspecificity of diagnosis and searches
restricted to presumed candidate genes. Regarding speci-
ficity, early studies estimatedMVP prevalence in the gen-
eral population to be 5%–15% and even as high as 35%,
but generally without clinical evidence of disease (Mar-
kiewicz et al. 1976; Procacci et al. 1976; Savage et al.
1983a, 1983b; Bryhn and Persson 1984; Warth et al.
1985; Levy and Savage 1987). Initial diagnosis relied
mainly on auscultation and single-dimensional echocar-
diography, which could produce the diagnosis in up to
21% of otherwise normal individuals (Markiewicz et al.
1976; Gilon et al. 1999). Nonspecificity continued with
two-dimensional (2D) echocardiography, as criteria were
broadened to maximize diagnostic frequency (Warth et
al. 1985; Levine et al. 1988). More recently, recognition
of the three-dimensional (3D) saddle shape of the valve
has eliminated false-positive diagnosis related to this
shape (Levine et al. 1987, 1988, 1989; Perloff and Child
1989; Nidorf et al. 1993). Without loss of sensitivity,
this recognition has increased specificity, with an esti-
mated frequency of 2.4% in a recent population-based
survey using the Framingham Heart Study (Freed et al.
1999, 2002a, 2002b). This has improved correspon-
dence between noninvasive diagnosis and the recognized
surgical and pathologic process (Marks et al. 1989; Ni-
dorf et al. 1993). The phenotypic basis for genetic studies
is now stronger, thereby increasing the likelihood of
identifying genes involved in the pathogenesis of MVP.
Recently, the first locus for nonsyndromic MVP,
MMVP1, has been mapped to chromosome 16p11.2-
p12.1 (Disse et al. 1999) in two of four families from a
surgical center. Further, X-linked myxomatous valvular
dystrophy, a rare disorder with histopathological fea-
tures similar to severe MVP, has been mapped to chro-
mosome Xq28 (Kyndt et al. 1998). The purpose of the
current study was to determine the chromosomal local-
ization of an MVP locus by performing a genomewide
search for linkage. Using a single large pedigree, we have
identified a second MVP locus (MMVP2) on chromo-
some 11p15.4, further demonstrating genetic heteroge-
neity and setting the stage for the molecular identifica-
tion of responsible genes. Such knowledge will increase
our understanding of pathogenesis, with the ultimate
potential of developing targeted therapy and possibly
preventing disease progression.
This study was carried out using the pedigree shown
in figure 1. The proband was identified as a volunteer in
a course teaching echocardiographic imaging. The study
was approved by the institutional review board at Mas-
sachusetts General Hospital, and all patients signed in-
formed consent forms prior to enrollment. Two-dimen-
sional echocardiograms were obtained on all available
family members, using a 2.5-MHz transducer with com-
plete parasternal, apical, subcostal, and suprasternal
views and color Doppler assessment of valvular regur-
gitation. The echocardiograms were read separately by
two readers (L.A.F. and R.A.L.) whowere blind to clinical
status. Currently accepted 2D echo criteria based on the
3D shape of the valve were used, and diagnosis of MVP
was based on maximal superior mitral leaflet displace-
ment during systole, relative to a line connecting the an-
nular hinge points (Levine et al. 1987, 1988, 1989;Marks
et al. 1989; Perloff and Child 1989; Nidorf et al. 1993).
Anterior and posterior leaflet displacements were mea-
sured in the parasternal and apical long-axis views, which
were scanned to visualize all three posterior leaflet scal-
lops sequentially. Because the lateral scallop is the most
difficult to evaluate from these views, its displacement
was also measured in the apical four-chamber view (Lev-
ine et al. 1988; Shah 1994), but it was always confirmed
in the long-axis scans. Mitral leaflet thickness was ex-
amined during diastasis at the midportion of the leaflet,
excluding focal thickening and chordae (Chandraratna
et al. 1984; Levine et al. 1988; Weissman et al. 1994).
On the basis of prior clinical and prognostic studies,
subjects were classified as having MVP if displacement
exceeded 2 mm. In addition, the degree of leaflet thick-
ening was qualitatively assessed (Chandraratna et al.
1984; Nishimura et al. 1985; Levine et al. 1988; Marks
et al. 1989; Perloff and Child 1989; Nidorf et al. 1993).
Although borderline degrees of displacement (2mm) are
not associated with increased leaflet thickness, mitral re-
gurgitation, left atrial enlargement, valve-related compli-
cations, or progression over a period of 10 years, for
this study, we considered these individuals indeterminate
rather than unaffected (Levine et al. 1988; Nidorf et
al. 1993; Vivaldi et al. 1994).
The complete pedigree contains 41 individuals in 5
generations, with both founders of Western European de-
scent (fig. 1). Echocardiograms and DNA were obtained
on 28 subjects (11 males and 17 females) of whom 12
were diagnosed with MVP, 3 were found to have an
indeterminate phenotype, and the remaining 13 were
classified as unaffected. The echocardiographic charac-
teristics of the affected patients are provided in table 1.
No extracardiac manifestations of connective-tissue ab-
normalities or Marfan syndrome were present in any
family members. Participating subjects’ age ranged 3–73
years; however, the 2 unaffected individuals under the
age of 6 years (25075, 25086) were excluded from the
analysis.
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Figure 1 Pedigree of family with MVP showing chromosome 11 haplotypes. Affected, unaffected, and indeterminate individuals are shown
as blackened, unblackened, and gray symbols, respectively. Patient ID codes are shown beneath the symbol. Symbols with a question mark (?)
represent individuals who did not participate in the study. An asterisk (*) indicates individuals who were used in the GENEHUNTER analysis.
Spouses of 25077 and 25065 were phenotyped, but DNA was unavailable. A black bar represents the disease chromosome, with the location
of recombination events marked as “X.” The marker order for all haplotypes is shown next to individual 25067.
Blood samples were collected on all family members at
the time of echocardiography. Genomic DNA was pre-
pared from either transformed lymphoblast cell lines
(Anderson and Gusella 1984) using the SDS-proteinase
Kmethod followed by phenol extraction or directly from
blood with the Nucleon II kit (Amersham). As part of
the genome scan, genotyping was performed using 374
genetic markers that make up the MGH Genomics Core
Facility linkage panel, the majority of which are from
the ABI Prism Linkage Mapping Set v. 2 (Perkin Elmer
Applied Biosystems). If additional map resolution was
needed, markers from the Cooperative Human Linkage
Center Weber Human Screening Set v. 8 (Research Ge-
netics) was used. All markers were amplified according
to the individual manufacturer’s recommended guide-
lines. PCR was performed using a PE 9700 thermocycler
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Table 1
Echocardiographic Characteristics of Affected Pedigree Members
ID No.
Age
(years) Sex MVP Type
Leaflet
Thickening
LAa
(mm)
LVIDdb
(mm)
EFc
(%) MR
25074 73 F Bileaflet Yes 37d 43d 68d Severe
25080 52 F Bileaflet Yes 46 57 61 Severe
25077 48 M Posterior Yes 35 32 64 Mild
25069 46 M Mild bileaflet Yes 38 46 65 Mild
25272 44 M Mild posterior Yes 31 50 74 Trace
25065 32 M Mild posterior Yes 27 47 64 None
25081 29 F Bileaflet Yes 30 47 64 Trace
25068 6 F Mild posterior Yes 20 30 66 Trace
25083 9 F Bileaflet Yes 20 38 73 Trace
25085 6 F Mild posterior Yes 20 34 68 None
25270 11 F Mild posterior Yes 30 42 62 Mild
26658 51 F Posterior No 31 40 57 Trace
a LA p left atrial diameter.
b LVIDd p left ventricular internal diameter (diastolic).
c EF p ejection fraction.
d Individual 25074 had mitral valve replacement for bileaflet MVP with severe MR; values
are postoperative.
(Applied Biosystems), and the products were run on an
ABI377 automated DNA sequencing system (Applied
Biosystems). GeneScan and Genotyper software packages
were used for allele identification and sizing. Additional
markers for fine mapping were identified from the Ge-
nome Database (GDB), and PCR was performed using
a total volume of 15 mL with ∼100 ng of genomic DNA;
20 pmol of each primer; 0.5 U Taq polymerase; 1.5 mM
MgCl2; 50 mM KCl; 200 mM dATP, dCTP, and dTTP;
20 mM dGTP; and 0.1 mCi a(32P)-dGTP. PCR was per-
formed on the PTC-100 thermal cycler (MJ Research)
using the following cycles: initial denaturation at 94C
for 2 min, followed by 30 cycles of 94C for 20 s, 53C–
60C for 20 s, and 72C for 20 s, concluding with a final
extension step of 72C for 2 min. Annealing tempera-
tures were optimized for each set of primers, and PCR
products were electrophoresed on a 6% acrylamide gel.
The data were analyzed assuming an autosomal domi-
nant mode of inheritance with incomplete penetrance and
a disease gene frequency of 0.005, with a phenocopy rate
of 1% to account for the high incidence of sporadicMVP,
as in the chromosome 16 linkage study (Disse et al.
1999). Penetrance for adults over age 15 years was set
at 95% for females, 63% for males, and at 32% and
21%, respectively, for those below age 15 years, to ac-
count for sex and age differences in familial studies re-
ported elsewhere (Devereux et al. 1982). Individuals des-
ignated indeterminate were coded as “unknown” for the
analysis. We also performed nonparametric (NPL) analy-
sis for all chromosomes using the GENEHUNTER pro-
gram (Kruglyak et al. 1996). Because the memory con-
straints of this program cannot accommodate allmembers
of this pedigree together, the pedigree was trimmed for
analysis according to standard convention (individuals
analyzed are shown in fig. 1).
A simulation study on the pedigree using all individu-
als with available DNA was performed using the SLINK
program (Ott 1989; Weeks et al. 1990). Five hundred
replicates were simulated using the above model. Two-
point LOD scores between the disease and individual
markers were calculated with the MLINK program of
the FASTLINK 3.0P package (Cottingham et al. 1993),
a faster version of the original LINKAGE package (La-
throp and Lalouel 1984; Lathrop et al. 1984, 1986).
This analysis generated a maximum parametric LOD
score of 3.88, suggesting that this family was sufficiently
powerful to detect linkage.
Prior to the genome scan, representative markers cov-
ering theMMVP1 region on chromosome 16 were tested
for linkage. Parametric GENEHUNTER analysis across
the previously reported MMVP1 locus region on chro-
mosome 16 using the markers D16S404-D16S3103-
D16S420-D16S3133-D16S3068-D16S3080-D16S515
yielded two-point LOD scores with range0.90–2.81
at and a maximum multipoint LOD score ofvp 0
0.50 between the markers D16S3080 and D16S515.
The maximum score achieved for the NPL analysis was
0.18 ( ) and occurred at the same position (dataPp .42
not shown). Evaluation of the multipoint LOD scores
and haplotypes across this region effectively excluded
linkage of our family to the MMVP1 locus.
Following exclusion of linkage toMMVP1, the entire
genome scan was performed and the data analyzed using
both LINKAGE and GENEHUNTER. A two-point LOD
score of 1.48 at was observed for the markervp 0.1
D11S1338, with a corresponding NPL score of 9.29
Reports 1555
Table 2
Two-Point Parametric LOD Scores of Chromosome 11 Markers
A. Entire Family
Marker cMa
LOD SCORE AT v
.00 .01 .05 .10 .20 .30 .40
D11S4046 2.8 .64 .16 .48 .72 .75 .58 .31
D11S4088 7.0 1.59 1.02 .13 .31 .58 .54 .33
D11S1923 8.6 1.87 1.45 .62 .16 .21 .27 .18
D11S4124 11.1 .41 .40 .37 .32 .24 .16 .08
D11S2349 12.3 .38 .43 .55 .58 .47 .27 .09
D11S1338 12.9b .93 1.07 1.38 1.48 1.34 .98 .51
D11S1323 13.0b .42 .38 .26 .14 .04 .12 .11
D11S1331 13.1b 2.65 2.36 1.67 1.18 .62 .30 .11
D11S932 14.5 1.47 1.19 .53 .12 .20 .23 .13
D11S4465 16.1 1.55 1.39 .98 .68 .35 .17 .06
B. Affected Individuals Only
Marker cMa
LOD SCORE AT v
.00 .01 .05 .10 .20 .30 .40
D11S4046 2.8 .31 .71 1.08 1.13 .93 .63 .30
D11S4088 7.0 .84 1.23 1.58 1.59 1.33 .92 .46
D11S1923 8.6 .34 .59 .90 .96 .83 .59 .30
D11S4124 11.1 .45 .44 .40 .35 .25 .16 .08
D11S2349 12.3 1.18 1.15 1.04 .89 .56 .24 .03
D11S1338 12.9b 2.76 2.71 2.50 2.24 1.70 1.11 .52
D11S1323 13.0b 1.91 1.87 1.69 1.47 1.03 .61 .25
D11S1331 13.1b 1.65 1.45 .98 .66 .31 .13 .03
D11S932 14.5 .06 .11 .47 .64 .65 .47 .21
D11S4465 16.1 .84 .75 .52 .35 .16 .07 .02
a Marker location on the Marshfield sex-averaged linkage map.
b Marker order is discrepant between the Marshfield genetic map and the HGB
physical map. Locations were adjusted to reflect the physical order.
( ), calculated under the assumption of equal al-Pp .008
lele frequencies of 0.10. D11S1338 was the only marker
in the scan to yield a two-point LOD score 11.0. Two
othermarkers (D1S2134 andD4S1539) had positiveNPL
scores ( ) and positive LOD scores (!1.0); however,P ! .05
GENEHUNTER analysis across these chromosomal
regions did not support linkage. Additional markers were
subsequently genotyped in the region of D11S1338, and
the data were analyzed using actual allele frequencies
obtained from the CEPH Genotype Database. Allele fre-
quencies were not available for D11S2349; therefore,
we genotyped 44 CEPH parents and estimated the fre-
quencies as: , , , and1p 53.4% 2p 28.4% 3p 3.4%
. The two-point parametric LOD scores are4p 14.8%
shown in table 2A. The highest two-point LOD score
observed was 1.48 at for the marker D11S1338.vp 0.1
Multipoint analysis across this region of the chromo-
some (fig. 2A) showed a positive region between the
markers D11S1923 and D11S1331 that peaks with a
LOD score of 3.12, which is highly suggestive of linkage
(Lander and Kruglyak 1995). Nonparametric analysis
across this interval was highly significant (fig. 2B), with
a maximum NPL of 38.59 ( ). The resultsPp .000397
of the parametric and nonparametric analyses support
linkage ofMVP in this family to a 4.3-cM region between
the markers D11S1923 and D11S1331. Next, haplo-
types were manually constructed for all members of the
pedigree and confirmed with the haplotypes generated
by GENEHUNTER (fig. 1). Examination of the hap-
lotypes confirms the segregation of a common haplotype
with MVP in this family. The haplotypes also show that
eight unaffected individuals (25071, 25078, 25072,
25070, 25075, 26659, 26067, and 25086) are nonex-
pressing carriers of the haplotype. With the exception
of one adult female (25071) and one 18-year-old male
(25070), all of these individuals are below age 15 years,
which is consistent with a model of age-dependent re-
duced penetrance. Further, two of these are under age 6
years (25075 and 25086), which we consider below the
minimal age of accurate MVP detection. We therefore
performed an affecteds-only parametric analysis using
LINKAGE to take into account the observed age-de-
pendent penetrance in MVP. This analysis was carried
out with the same individuals used in the GENE-
Figure 2 GENEHUNTER analysis of the MMVP2 locus. Distances between the markers correspond to the marker map in table 1.
A, Graph of multipoint parametric LOD scores. B, Graph of multipoint NPL scores.
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HUNTER analysis (fig. 1). These scores, as expected, are
significantly higher and are presented in table 2B.
We next examined the haplotypes of the affected pedi-
gree members to determine the boundaries of the linked
region. All affected members in our family share a four-
marker core haplotype of 169-1-265-205 for the mark-
ers D11S4124-D11S2349-D11S1338-D11S1323. A re-
combination event in individual 25272 betweenmarkers
D11S1923 and D11S4124 defines the proximal bound-
ary of the linked region. Likewise, two independent and
informative recombination events between D11S1323
and D11S1331 in individuals 25068 and 25083 strongly
establish the distal boundary of the candidate region.
The region between the linked markers D11S1923 and
D11S1331 is located between 3.58 Mb and 8.03 Mb on
chromosome 11p15.4 of the June 2002 freeze of the
Human Genome Browser (HGB). This 4.45-Mb span,
which still contains several large gaps in sequence cov-
erage, contains 46 known genes. Further, examination
of the UniGene clusters suggests the presence of as many
as 90 additional transcripts. The preponderance of genes
in this region, coupled with the lack of any obvious
functional candidates, suggests that narrowing the in-
terval by analysis of a more detailed haplotype is crucial
to the efficient identification of the gene responsible for
MVP in this family.
Our analysis demonstrates that a second locus for
autosomal dominant MVP maps in a 4.3-cM region
between the markers D11S1923 and D11S1331 on
chromosome 11p15.4. This locus has been desig-
nated “MMVP2” and the symbol approved by the Hu-
man Genome Organization (HUGO) Gene Nomencla-
ture Committee. Further, our results confirm the genetic
heterogeneity ofMVP, which had been suggested by link-
age of the chromosome 16 locus in only two of four
families studied by Disse et al. (1999). In contrast with
prior negative studies (Henney et al. 1989; Wordsworth
et al. 1989), the identification of two MVP loci on chro-
mosomes 11 and 16 demonstrates the strength of the
current approach, which combines new and more-spe-
cific diagnostic criteria for MVP with systematic genome
scanning.
Genetic heterogeneity provides the opportunity to ex-
plore the relationship between various genetic defects and
differences in disease expression, natural history, and
mortality, as has been shown for familial hypertrophic
cardiomyopathy (Solomon et al. 1990; Coonar and Mc-
Kenna 1997; Maron et al. 1998; Seidman and Seidman
1998; Tesson et al. 1998). Analogous to familial hyper-
trophic cardiomyopathy, the noninvasive diagnosis of
disease requires criteria of variable sensitivity and spec-
ificity for such measures as septal thickness or mitral
leaflet displacement, established by correlationwith con-
comitant echocardiographic and clinical abnormalities.
In the hypertrophic condition, it has been found that the
familial context successfully permits the use of more sen-
sitive criteria without sacrificing specificity (Tesson et al.
1998). In the MVP context, it is hoped that genetic stud-
ies can also lead to a better understanding of clinical and
echocardiographic observations. For example, patients
with MVP and thick leaflets are much more likely to
manifest regurgitation and related complications when
compared with patients with MVP and thin leaflets
(Nishimura et al. 1985; Marks et al. 1989; Nidorf et al.
1993), although the same family may contain a spectrum
of leaflet thickness (Zuppiroli et al. 1998). This may
represent two stages in disease development, variable
expression, or perhaps genetic heterogeneity.
Genetic localization of MVP loci will lead to the iden-
tification of mutations in genes that underlie the molecu-
lar basis of the disorder. Not only will this result in in-
creased diagnostic accuracy, which will in turn reduce the
well-documented anxiety that often accompanies the di-
agnosis of MVP (Scordo 1998; Benjamin 2001), but it
may also uncover genotype-phenotype relationships that
will advance treatment by allowing for prediction of dis-
ease-progression patterns. This is important because the
disease often manifests clinically in the 5th or 6th decade
of life through presentation as a severe cardiac event.
Earlier targeted intervention to reduce leaflet stresses in
genetically susceptible individuals, as in the case of aortic
dilatation in Marfan syndrome (Shores et al. 1994),
could potentially prevent the progression and compli-
cations often associated with mitral valve prolapse.
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